2022 Global Life Sciences Outlook
Digitalization at scale: Delivering on the promise of science
Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. How will life sciences companies continue to respond and what areas can they build resiliency going forward?
Measuring the return from pharmaceutical innovation 2021
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and identifies lessons that can help change the R&D paradigm towards a future with higher returns.
Never the same again: How COVID-19 created seismic change in global life sciences regulations
A global report for life sciences executives and regulators
COVID-19 accelerated global scientific and regulatory innovation and collaboration in the life sciences industry. To stretch to new limits, the momentum must continue.
Enhancing clinical trial diversity
Stakeholder perspectives on advancing research through representative clinical trials
Racial and ethnic diversity among clinical trial participants is important to support science-driven strategies aimed at understanding the needs of those who are affected by the disease or condition being investigated. How can the biopharma industry achieve this? The answer lies in multistakeholder partnerships.
Can more US consumers be swayed to take the COVID-19 vaccine? Overcoming access, trust, hesitancy, and other barriers
Findings from the 2021 consumer vaccine survey
Consumer sentiment around vaccines continues to shift as the pandemic evolves. Our survey studied what worked and what did not, in terms of vaccine deployment strategies, and the lessons learned can be applied to future vaccination programs.
FT Global Pharmaceutical & Biotechnology Conference